US EditionPublished • loading... • Updated
New study links Kaftrio treatment to lower insulin doses in CFRD
Summary by Cystic Fibrosis News Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
New study links Kaftrio treatment to lower insulin doses in CFRD
Lower insulin doses and less blood sugar variability were observed one year after adults with cystic fibrosis-related diabetes (CFRD) started Kaftrio. That’s according to results from the DIATRIM study (NCT06331000), a real-world, multicenter observational study conducted at 13 centers in France. Researchers retrospectively analyzed data from adults with CFRD who began Kaftrio, which is marketed as Trikafta in the U.S. However, there were no sig…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
